Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

VICTORIA, BC, July 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diff

PR NewswireJul 8 07:00 ET

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control and Prevention estimates that knee OA affects more than 30 million people in the U.S. al

PR NewswireJul 3 17:00 ET

Eupraxia Pharmaceuticals Announces Voting Results From Annual General and Special Meeting of Shareholders

Stockhouse Jun 6 17:00 ET

Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data From the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

07:02 AM EDT, 06/05/2024 (MT Newswires) -- Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheu

MT NewswiresJun 5 07:02 ET

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

Stockhouse May 22 07:00 ET

Update On Eupraxia Pharmaceuticals: Now Up 40% In US After Hours, Was Up As Much As 70%

Eupraxia Pharmaceuticals Inc. (EPRX.TO and NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with signi

MT NewswiresMay 21 17:13 ET